Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS) introduced TherapyWise, a cloud-based analytics capability integrated into NxView 4.0, the FDA 510(k)-cleared software platform used with the NxStage System One for kidney replacement therapy in U.S. acute and critical care settings.

TherapyWise aggregates retrospective program-level data from ICU kidney replacement therapy, summarizing metrics such as average delivered versus set dose, treatment time per cartridge, and alarm frequency trends. It is designed for oversight and quality improvement, not real-time patient-specific decision-making, which remains the responsibility of attending clinicians.

Market Context

FMS carried a low short-interest signal in the current risk context, providing limited short-positio...

Analysis

FMS carried a low short-interest signal in the current risk context, providing limited short-positioning context for this analytics introduction. The main watchpoint is TherapyWise’s stated retrospective scope rather than real-time, patient-specific decision-making.

Key Figures

Announcement date: July 20, 2026 NxView version: NxView 4.0 FDA clearance: 510(k)-cleared +3 more

6 metrics

Announcement date July 20, 2026 TherapyWise introduction

NxView version NxView 4.0 Software platform containing TherapyWise

FDA clearance 510(k)-cleared NxView 4.0 in the United States

Dialysis patients worldwide 4.5 million patients Patients regularly undergoing dialysis treatment

Dialysis clinics 3,539 clinics Fresenius Medical Care global network

Patients served Approximately 290,000 patients Dialysis treatments provided globally

Historical Context

5 past events · Latest: Jun 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 03	Digital platform launch	Positive	+1.7%	Kinexus launched worldwide as a unified digital platform for home dialysis programs.
May 28	Share buyback launch	Positive	+0.3%	First buyback tranche launched with authorization for up to EUR 600 million.
May 27	Renal research showcase	Positive	-0.1%	Company highlighted renal research and digital innovation at ERA Congress 2026.
May 26	Share buyback announcement	Positive	-0.3%	New share repurchase program announced with total volume around EUR 1 billion.
May 21	Annual meeting update	Positive	+1.4%	Annual meeting reported higher profitability, reduced leverage, and approved shareholder distributions.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent digital and innovation announcements produced mixed reactions, while the strongest positive response followed the kinexus launch.

Key Terms

510(k), kidney replacement therapy, point of care

3 terms

510(k) regulatory

"FDA 510(k)-cleared software platform for use with the NxStage System One"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

kidney replacement therapy medical

"retrospective, program-level insight into kidney replacement therapy"

Kidney replacement therapy is medical treatment that takes over the blood-cleaning and fluid-balancing jobs of failed kidneys, most commonly via dialysis machines or by transplanting a donor kidney. Investors watch it because it drives durable demand for devices, drugs, clinics and transplant services, and changes in technology, regulation or reimbursement can materially affect costs, patient access and the revenues of companies in the renal care market.

point of care medical

"existing data generated at the point of care"

Point of care is the place and moment where a patient receives medical attention or testing — for example, a doctor's office, clinic, bedside, or urgent care — rather than a distant laboratory. For investors, point‑of‑care products matter because they speed diagnosis and treatment, lower costs, and can increase demand for portable tests and devices in many healthcare settings, much like having a home thermometer instead of sending samples away.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settings
• Available within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care's FDA 510(k)-cleared software platform for kidney replacement therapy in the United States
• Aggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability

BAD HOMBURG, Germany, July 20, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the introduction of TherapyWise™, a cloud-based analytics capability available within NxView™ 4.0, the Company's FDA 510(k)-cleared software platform for use with the NxStage® System One™ in the United States. TherapyWise is designed to provide retrospective, program-level insight into kidney replacement therapy (KRT) delivered in acute and hospital critical care settings.

Kidney replacement therapy in the Intensive Care Unit (ICU) generates large volumes of clinical and operational data, yet trends related to therapy delivery, workflow interruptions, and alarm frequency can be difficult to assess without standardized metrics and aggregated views. TherapyWise consolidates existing data generated at the point of care and presents longitudinal summaries intended to support oversight of KRT programs across ICU units and time periods.

"Digital solutions play an increasingly important role in how critical care teams understand and manage complex therapies," said Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care. "TherapyWise reflects our continued focus on innovation in critical care by applying data analytics. This helps hospital and clinical leaders gain visibility into how kidney replacement therapy is delivered across their organizations, supporting informed discussions around workflow, consistency, and quality improvement."

TherapyWise works by securely transmitting data from the NxStage System One with NxView to a cloud‑based platform, where information is aggregated and displayed across predefined performance indicators. These include program‑level metrics including average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends. The software is intended to support retrospective review and program oversight and is not designed for real‑time, patient‑specific clinical decision‑making, which remains the responsibility of attending clinicians.

TherapyWise is part of Fresenius Medical Care's NxView 4.0 software platform and broader critical care portfolio, which combines digital infrastructure, clinical expertise, and secure data management to support hospital teams responsible for kidney replacement therapy programs.

To learn more about TherapyWise, please visit https://freseniusmedicalcare.com/en-us/products/critical-care/therapywise/.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com 

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-therapy-302829320.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What is TherapyWise in Fresenius Medical Care's (NYSE:FMS) NxView 4.0 platform?

TherapyWise is a cloud-based analytics capability within NxView 4.0 for NxStage System One. According to Fresenius Medical Care, it provides retrospective, program-level insight into kidney replacement therapy in acute and hospital critical care, aggregating clinical and operational data for standardized review.

How does TherapyWise support kidney replacement therapy programs in ICU settings for FMS?

TherapyWise supports kidney replacement therapy programs by consolidating data from NxStage System One with NxView into longitudinal summaries. According to Fresenius Medical Care, it helps hospital and clinical leaders assess trends in delivered dose, treatment time per cartridge, workflow interruptions, and alarm frequency across ICU units.

Is TherapyWise intended for real-time clinical decision-making for Fresenius Medical Care's NxStage System One?

TherapyWise is not intended for real-time, patient-specific clinical decision-making. According to Fresenius Medical Care, the software supports retrospective review and program oversight, while real-time treatment decisions remain the responsibility of attending clinicians managing kidney replacement therapy at the bedside.

What key metrics does TherapyWise analytics track for Fresenius Medical Care (FMS) kidney replacement therapy?

TherapyWise tracks program-level metrics such as average delivered dose versus set dose, average treatment time per cartridge, and alarm frequency trends. According to Fresenius Medical Care, these predefined performance indicators help standardize assessment of kidney replacement therapy delivery over time and across ICU programs.

Is TherapyWise available only in the United States for Fresenius Medical Care's NxStage System One?

TherapyWise is available within NxView 4.0, the FDA 510(k)-cleared software platform for NxStage System One in the United States. According to Fresenius Medical Care, this capability is designed specifically to support U.S. acute and hospital critical care kidney replacement therapy programs.

How does TherapyWise transmit and manage data for Fresenius Medical Care (NYSE:FMS)?

TherapyWise securely transmits data from NxStage System One with NxView to a cloud-based platform for aggregation. According to Fresenius Medical Care, the system then displays information across predefined performance indicators, enabling retrospective analysis of kidney replacement therapy at the program level.